20 Healthcare Stocks Moving In Monday's Pre-Market Session

Gainers

• Sorrento Therapeutics, Inc. SRNE stock rose 45.27% to $9.82 during Monday's pre-market session. The most recent rating by H.C. Wainwright, on Mar 30, is at Buy, with a price target of $24.

• Aurora Cannabis, Inc. ACB shares rose 30.28% to $14.20. The most recent rating by Piper Sandler, on May 15, is at Neutral, with a price target of $10.

• Diffusion Pharmaceuticals, Inc. DFFN stock rose 23.70% to $1.67.

• Fulgent Genetics, Inc. FLGT stock rose 23.25% to $20.20. The most recent rating by Credit Suisse, on May 5, is at Neutral, with a price target of $11.

• Kitov Pharma, Inc. KTOV stock moved upwards by 22.10% to $0.60.

• Trevena, Inc. TRVN shares rose 12.38% to $1.18.

• Vir Biotechnology, Inc. VIR shares increased by 11.30% to $33.78. The most recent rating by Baird, on Mar 27, is at Underperform, with a price target of $20.

• Auris Medical Holding, Inc. EARS shares rose 11.21% to $1.19.

• HEXO, Inc. HEXO shares increased by 10.99% to $0.59. The most recent rating by Roth Capital, on Mar 31, is at Neutral, with a price target of $1.

• Mesoblast, Inc. MESO stock rose 9.88% to $13.01.

Losers

• ChemoCentryx, Inc. CCXI shares decreased by 10% to $48.42 during Monday's pre-market session. The most recent rating by JP Morgan, on May 14, is at Overweight, with a price target of $64.

• PDL BioPharma, Inc. PDLI stock fell 8.81% to $2.90.

• Titan Pharmaceuticals, Inc. TTNP shares decreased by 7.64% to $0.25.

• Tetraphase Pharmaceutical, Inc. TTPH stock declined 6.85% to $2.04. According to the most recent rating by Gabelli & Co., on Mar 17, the current rating is at Sell.

• Aptevo Therapeutics, Inc. APVO shares fell 6.40% to $5.12.

• PLx Pharma, Inc. PLXP shares declined 6.25% to $2.55.

• Seneca Biopharma, Inc. SNCA shares decreased by 5.98% to $0.86.

• Atossa Therapeutics, Inc. ATOS stock fell 5.88% to $1.60.

• Menlo Therapeutics, Inc. MNLO shares fell 5.33% to $1.60. The most recent rating by HC Wainwright & Co., on May 12, is at Buy, with a price target of $2.

• VistaGen Therapeutics, Inc. VTGN shares decreased by 5% to $0.38.